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Abstract: To find new anti-cancer drug therapies, we wanted to exploit homeostatic vulnerabilities
within Tuberous Sclerosis Complex 2 (TSC2)-deficient cells with mechanistic target of rapamycin
complex 1 (mTORC1) hyperactivity. We show that nelfinavir and mefloquine synergize to selectively
evoke a cytotoxic response in TSC2-deficient cell lines with mTORC1 hyperactivity. We optimize
the concentrations of nelfinavir and mefloquine to a clinically viable range that kill cells that lack
TSC2, while wild-type cells tolerate treatment. This new clinically viable drug combination causes
a significant level of cell death in TSC2-deficient tumor spheroids. Furthermore, no cell recovery
was apparent after drug withdrawal, revealing potent cytotoxicity. Transcriptional profiling by RNA
sequencing of drug treated TSC2-deficient cells compared to wild-type cells suggested the cytotoxic
mechanism of action, involving initial ER stress and an imbalance in energy homeostatic pathways.
Further characterization revealed that supplementation with methyl pyruvate alleviated energy
stress and reduced the cytotoxic effect, implicating energy deprivation as the trigger of cell death.
This work underpins a critical vulnerability with cancer cells with aberrant signaling through the
TSC2-mTORC1 pathway that lack flexibility in homeostatic pathways, which could be exploited with
combined nelfinavir and mefloquine treatment.
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1. Introduction
Mechanistic (formally mammalian) target of rapamycin (mTOR) is often referred to as a master
regulator of cell growth [1]. mTOR is a serine/threonine protein kinase that coordinates cell growth,
metabolism, protein synthesis and autophagy as a protein kinase complex, termed mTOR complex
1 (mTORC1). mTORC1 is fundamentally involved in the build-up of cellular biomass, which is
rate-limiting for hyper-proliferative cancer cells. As well as cell growth control, mTORC1 promotes
metabolic transformation, neovascularization, cell survival and metastasis (reviewed in reference [2]).
Genetic mutations leading to mTORC1 hyperactivation often occur in sporadic cancer but also underlie
several tumor predisposition syndromes, such as Tuberous Sclerosis Complex (TSC) [3] and Cowden
disease/PTEN hamartoma syndrome (reviewed in reference [4]). mTORC1 hyperactivity has also
been identified in numerous cancer types including lung (>50% in both small cell and non-small cell
lung cancer cases [5,6]), ovarian (approximately 70% of ovarian cancers [7]), renal cell carcinoma [8]
and head and neck cancers [9]. Although uncommon, activating mutations within the kinase domain
of mTOR occurs in cancer [10,11]. More frequently, genes that function upstream of the mTORC1
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signaling pathway are mutated in cancer, such as PI3K, PTEN and RAS, which then cause aberrant
signal transduction through mTORC1 to drive cancer growth [12].
TSC is an autosomal dominant condition caused by mutations in either TSC1 or TSC2 and is
characterized by mTORC1 hyperactivity, tumor growth in multiple organs, neurocognitive problems
and epilepsy [13]. TSC1 and TSC2 form a tumor suppressor protein complex that functions as
a GTPase-activating protein (GAP) towards the small G-protein, Ras homologue enriched in brain
(Rheb) [14,15]. When associated with TSC1, the GAP function of TSC2 switches Rheb from its active
GTP-bound state to an inactive GDP-bound state to turn off mTORC1. Consequently, loss-of-function
mutations in either TSC1 or TSC2 cause Rheb to become predominantly GTP-loaded, thereby
constitutively turning on mTORC1. mTORC1 inhibitors, such as rapamycin analogues (rapalogues),
are currently used as the first-line therapy to treat TSC and are effective at shrinking tumors and
delaying disease progression. However, mTORC1 inhibitors are cytostatic meaning that TSC tumor
cells regrow after treatment withdrawal (reviewed in reference [16,17]). This cytostatic nature of mTOR
inhibitors is a principal reason why rapalogues have had limited clinical success in the cancer setting,
where the lack of cytotoxicity leads to acquired drug resistance (reviewed in reference [2]).
To overcome the shortcomings of directly targeting mTORC1 in cancer, an alternative therapy
might be to exploit the intrinsic vulnerabilities of cancer cells that have constitutive mTORC1 activation.
In principle, you could take advantage of the cancer’s inability to restore homeostatic balance during
prolonged periods of drug induced cell stress to trigger a cytotoxic response. In contrast to cancer cells,
non-cancerous cells would have greater flexibility in their homeostatic pathways, allowing them to
better tolerate drug treatment. As loss of TSC1/2 and mTORC1 hyperactivity results in an increased
burden of unfolded protein within the endoplasmic reticulum (ER), which causes membrane expansion
of the ER and activation of the unfolded protein response (UPR) [18], a possible therapy would be to
employ ER stress inducers. To enhance the cytotoxic effect, you could also target cell survival pathways,
such as autophagy. Previously, we examined the combined effect of chloroquine (an autophagy
inhibitor) with nelfinavir (an ER stress inducer), which selectively enhanced cell death in mTORC1
hyperactive cells [19]. Nelfinavir is a clinically approved HIV inhibitor that induces ER stress and
shows promise as an anti-cancer agent [20]. While these clinically viable drugs were previously shown
to be selectively cytotoxic to mTORC1-active cells, combined chloroquine and nelfinavir treatment
was not sufficient to kill all the cells, showing a heterogeneous drug effect and a significant level of
drug resistance. In this current study, we wanted to refine our previous combinatory drug therapy
to enhance their cytotoxic potency. To do this, we considered dual treatment with nelfinavir and
mefloquine, which appeared to kill a higher percentage of Tsc2-deficient cells when compared to
nelfinavir and chloroquine in our initial analysis [19]. Mefloquine is a chloroquine derivative used
in both the prevention and treatment of malaria and unlike chloroquine, more readily crosses the
blood-brain barrier. Mefloquine has been reported to inhibit autophagy (via blocking the formation of
autophagosomes [21]), to induce reactive oxygen species (ROS) [22] and to prevent PI3K/Akt/mTORC1
signaling [23]. In this study, we demonstrate that nelfinavir and mefloquine show therapeutic promise
as a drug combination that has high potency to kill TSC2-deficient cells and cancer cells with high
mTORC1 activity.
2. Results
2.1. Nelfinavir and Mefloquine Synergize, and Selectively Kill Tsc2-Deficient Cell Lines
To build on our previous study [19] and to further explore the impact of nelfinavir and mefloquine
dual therapy, we tested the ability of nelfinavir and mefloquine to synergize and induce cell death.
Loss of cell viability was quantified with escalating concentrations of drug, either as single agents or
in combination using flow cytometry with DRAQ7 staining. DRAQ7 can only penetrate membranes
of cells that are compromised (i.e., are no longer viable). Loss of cell viability (determined by
an increase of DRAQ7 fluorescence) with single drug treatments for nelfinavir and mefloquine is
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shown in Figure 1A,B, respectively. To ascertain how synergistic this combination was, a range of
mefloquine concentrations were tested with a fixed 10 µM concentration of nelfinavir (Figure 1C).
Quantification of cell death was processed in CompuSyn using a non-constant ratio approach to
generate a Combination Index (CI) value, where it is considered that a score <1 is synergistic, a score
of 1 is additive, and a score >1 is antagonistic. Results reveal that 10 µM mefloquine was synergistic
with 10 µM nelfinavir to induce cell death in the Tsc2−/−mouse embryonic fibroblasts (MEFs) (CI
value = 0.03). Due to this finding, further assays were carried out using 10 µM mefloquine and 10 µM
nelfinavir. We observed selective cytotoxicity with the combinatory drug treatment in cells lacking
Tsc2, i.e., (37.6% −/+ 11.8 standard deviation (St-Dev) in the Tsc2+/+ MEFs versus 96% −/+ 2 in the
Tsc2−/−MEFs) (Figure 1D). Etoposide was employed as a positive control and induced cell death in
both the Tsc2+/+ and Tsc2−/−MEFs.
To confirm that the genetic loss of Tsc2 was responsible for selective cell death, mefloquine and
nelfinavir were then tested in ELT3 (Eker rat leiomyoma-derived) cells (Figure 1E), another model
of TSC [24]. Results were comparable to that observed in the Tsc2−/−MEFs, where ELT3-V3 cells
(lacking Tsc2) had a significant induction of cell death (76% −/+ 6.3) when compared to the rescued
ELT3-T3 with Tsc2 re-expressed (42%−/+ 5.4). To determine whether combined nelfinavir/mefloquine
drug treatment could also target sporadic cancer cell lines, we tested three mTORC1-hyperactive
cancer cells (Figure 1F). Results from flow cytometry showed that combined 10 µM nelfinavir with
10 µM mefloquine treatment caused a high degree of cytotoxicity in the MCF7 breast cancer cell line
(67% −/+ 8.30), in the HCT116 colorectal cancer cell line (96% −/+ 1.95), and in the NCI-H460 lung
cancer cell line (89% −/+ 2.5). As single drug treatments, nelfinavir and mefloquine were not cytotoxic
to MCF7 cells. As a mono-agent, mefloquine was observed to potently kill the HCT116 and NCI-H460
cell lines (but to a lesser degree when compared to combination treatment with nelfinavir). Etoposide
was used as a control, which was effective at killing the HCT116 and NCI-H460 cells, while the MCF-7
cells were notably resistant.
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Figure 1. Mefloquine and nelfinavir synergize to kill sc /−Mouse embryonic fibroblasts (MEFs),
ELT3-T3 and sporadic cancer cells. Dose response curve r ed in Tsc2+/+ and Tsc2−/−
MEFs using flow cytometry to s re cell death f llowing tr atment with (A) nelfinavir (NFV);
(B) mefloquine ( Q) and (C) combined mefloquine with a fixed concentration of 10 µM nelfinavir
(MQ/NFV); (D) Tsc2+/+ and Tsc2−/− MEFs; (E) ELT3-T3 and ELT3-V3; (F) MCF7, HCT116 and
NCI-H460 were treated with either DMSO, etoposide (ETO), 10 µM mefloquine (MQ), 10 µM nelfinavir
(NFV) or mefloquine combined with nelfinavir (MQ/NFV) for 48 h. Cells were then tested by flow
cytometry and cells were separated into viable and non-viable cell populations via DRAQ7 staining.
Statistical significance is shown with combination treated Tsc2−/−MEFs or the ELT3-V3 cells to their
wild-type controls, and comparing single drug treatment of mefloquine and combination with the
MCF7, HCT116 and NCI-H460.
2.2. Combined Nelfinavir and Mefloquine Treatment Inhibits Tumor Formation, Induces Cytotoxicity in
Tsc2−/− Spheroids, and Prevents Spheroid Outgrowth
To determine whether nelfinavir and mefloquine combination treatment prevents the formation
of tumors in vitro, Tsc2−/− MEFs w re grown in soft agar in th continued presence or absence
of dru over 14 days (Figure 2A). We observed that when combi ed, nelfinavir and mefloquine
significantly reduced colony growth compared to single drug treatments, which as mono agents
did not significantly reduce colony size. Average colony size was 49.1 µm +/− 19.27 in diameter
after nelfinavir/mefloquine treatment compared to 90.7 µm +/− 22.12 observed in samples treated
with dimethyl sulfoxide (DMSO). To examine whether drug treatments could induce cell death in
established tumor spheroids, Tsc2−/−MEFs were grown as spheroids and once established were then
incubated with either DMSO, nelfinavir or mefloquine (as single drug treatments or in combination)
for 4 days (Figure 2B). To measure loss of cell viability, spheroids ere DRAQ7-stained during drug
incubation. Intensity o DRAQ7 fluorescence was higher after combined treatment wi h nelfinavir and
mefloquine (1424 MFU (mean fluorescent units) −/+ 404), when compared to single drug treatment
with nelfinavir (668 MFU −/+ 146), and DMSO (768 MFU −/+ 214). Elevated DRAQ7 fluorescence
was also observed with single drug treatment with mefloquine (1216 MFU −/+ 328). Tumor spheroids
were transferred to plastic tissue culture plates to assess recovery and outgrowth of cells after drug
removal (Figure 2C). Cell outgrowth was measured over 72 h, and showed cell recovery from the tumor
spheroid after single drug treatment with either nelfinavir or mefloquine, although cell outgrowth was
much slower with mefloquine when compared to either DMSO or nelfinavir treatments. In contrast,
cells were unable to recover after combined treatment with mefloquine and nelfinavir, as observed
by no detectable outgrowth of cells over the 72 h period. These data reveal that the combination of
mefloquine and nelfinavir is effective at killing the bulk tumor.
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Figure 2. Mefloquine and nelfinavir prevents colony formation and spheroid growth. (A) Colony
formation was tested in Tsc2−/− MEFs seeded on soft ag r that were treated for 14 da s with
Dimethyl Sulfoxi e (DMSO), 10 µM mefloquine (MQ), 10 µM nelfinavir (NFV) or in combination.
Tumor diameters were measured using Image J; scale bar is 200 µm. Signifi ance was observed when
co paring combined nelfinavir and mefloquine treatment to DMSO v hicle control. (B) Tsc2−/−
MEF spheroids were treated under the same conditions as (A) for 96 h. DRAQ7 was supplemented
for the final 36 h to monitor cell death before images were taken and DRAQ7 fluorescence quantified.
(C) Spheroids treated in (B) were re-plated onto standard tissue culture plates and grown in drug-free
media. Images were taken every 24 h and the area of outgrowth calculated using Image J, scale bar is
200 µm and outgrowth area is graphed.
2.3. Homeostatic Balance is Lost in Tsc2−/−MEFs after Combination Treatment with Nelfinavir and Mefloquine
We postulated that the most likely mechanism of cell death would be because of prolonged ER
stress and an inability to recover. Therefore, we initially examined ER stress signaling. Western blots
were carried out on a panel of ER stress markers (inositol-requiring and ER-to-nucleus signaling protein
1α (IRE1α), activating transcription factor 4 (ATF4), C/EBP homologous protein (CHOP), growth arrest
and DNA damage-inducible protein (GADD34), and Sestrin 2 (SESN2)), with thapsigargin treatment as
a positive control. We observed a large difference in expression of ER stress markers when comparing
Tsc2−/− to their wildtype Tsc2+/+ controls (Figure 3A). For instance, the Tsc2−/−MEFs have a higher
level of IRE1α, ATF4, CHOP and GADD34 protein expression after thapsigargin and nelfinavir as
single drug treatments, while mefloquine weakly induced ER stress. The control cells exhibit a lower
basal level of ER stress and show little ER stress induction with single or combination treatments.
Analysis of p70 ribosomal protein S6 kinase 1 (S6K1) phosphorylation showed that Tsc2−/−MEFs
had a high level of mTORC1 activity that was not altered with drug treatments. To confirm that ER
stress was enhanced after treatment, X-box binding protein 1 (Xbp1) mRNA splicing was determined
(Figure 3B), revealing a higher level of Xbp1 mRNA splicing in Tsc2−/− cells after combination drug
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treatment when compared to the untreated Tsc2−/− and treated Tsc2+/+ controls. We also observed
a high level of Xbp1 mRNA splicing in untreated Tsc2−/−MEFs, showing that these cells have a higher
basal level of ER stress.
To assess transcriptional changes, RNA sequencing was carried out on mRNA samples generated
from Tsc2+/+ and Tsc2−/−MEFs treated with either DMSO or nelfinavir and mefloquine. We observed
elevated expression of ER stress genes in both Tsc2+/+ and Tsc2−/−MEF cell lines after combined
nelfinavir and mefloquine drug treatment, which was higher in the absence of Tsc2 (Figure 3C,D and
Table S1). We also observed elevated expression of ER stress genes in untreated Tsc2−/−MEFs when
compared to wildtype. Conversely, negative regulators of ER stress such as CREBRF and IMPACT were
expressed at higher levels in the Tsc2+/+ MEFs when compared to the Tsc2−/−MEFs (Figure 3E and
Table S2). The volcano plot illustrates the differential expression of genes involved in ER stress between
the Tsc2+/+ and Tsc2−/−MEFs after combined nelfinavir and mefloquine treatment (Figure 3E).
To determine the capacity of Tsc2+/+ and Tsc2−/−MEFs to effectively restore ER stress during
treatment, we examined the expression of ER stress proteins after combined nelfinavir and mefloquine
treatment at an early 6 h time point and at a longer 48 h time point. The 6 h time point reflects acute ER
stress induction after treatment, while the 48 h time point reflects ER stress recovery during prolonged
drug treatment (Figure 3F). In wildtype Tsc2+/+ MEFs, nelfinavir and mefloquine treatment increased
the expression of CHOP and ATF4 protein at 6 h. However, by 48 h the expression of ATF4 and CHOP
was restored back down to a level equivalent to untreated cells, indicating a complete recovery to the
ER stress signaling pathway in the Tsc2+/+ MEFs. Similarly, the Tsc2−/−MEFs also recovered from
ER stress at the 48 h time point. The ability to restore the ER stress signaling pathway in the Tsc2−/−
MEFs implies that the ER stress pathway is unlikely the main trigger that instigates the observed cell
death response.
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Figure 3. Mefloquine and nelfinavir drug combination causes increased ER stress in Tsc2−/−MEFs.
(A) Tsc2+/+ and Tsc2−/− MEFs were t eated with either DMSO, 1 µM thapsigargin (TPG), 10 µM
mefloquine (MQ), 10 µM nelfinavir (NFV), or mefloquin and nelfinavir combination for 6 h, where
indicated. Total protein levels of TSC2, IRE1α, ATF4, CHOP, GADD34, S6K1 and β-actin and S6K1
phosphorylated at Thr389 were detected by Western blot. (B) Xbp1 mRNA splicing was determined
from the same treatments as described in (A). PCR products were resolved on agarose gels (unspliced =
480 bp upper band, spliced = 454 bp lower band). (C–E) Tsc2+/+ and Tsc2−/−MEFs were treated with
either DMSO or mefloquine and nelfinavir combination (MQ/NFV) for 6 h before being processed for
RNA sequencing. A heat map for a panel of ER stress-linked genes is shown (C) and are graphed in (D).
(E) Differences of mRNA expression between Tsc2+/+ and Tsc2−/−MEFs treated with mefloquine
and nelfinavir is shown as a volcano plot and highlights ER stress genes. (F) Tsc2+/+ and Tsc2−/−
MEFs were treated with DMSO or mefloquine (MQ) and nelfinavir (NFV) combination for 6 h and 48 h.
Total protein levels of ATF4, IRE-1α, GADD34, CHOP and β-actin were determined by Western blot.
2.4. Cytotoxicity of Tsc2-Deficient Cells with Nelfinavir and Mefloquine is Energy Dependent
We next wanted to det rmi e whether mTORC1-hyperactivity wa important for the induction of
cell death. We carried out flow cytometry with DRAQ7 staining in Tsc2−/−MEFs, HCT116, NCI-H460
and MCF7 cells treated with either DMSO, or combination with nelfinavir and mefloquine in the
presence or absence of rapamycin for 48 h (Figure 4A). Rapamycin failed to rescue cell death in these
cell lines, showing that the cytotoxic effect of this drug combination is not prevented when mTORC1 is
inhibited. Control western blots showing that rapamycin treatment was sufficient to block ribosomal
protein S6 (rpS6) phosphorylation in these cells are shown (Figure 4B). As mefloquine is classically
known as an autophagy inhibitor, we next analyzed build-up of lipidated LC3 to measure autophagy
inhibition after treatment with either mefloquine or chloroquine after 3 h of treatment (Figure 4C).
While mefloquine by itself did not cause an increase of lipidated LC3, there was an increase in the
LC3-II lipidated isoform when mefloquine was combined with nelfinavir. It should be noted that the
level of lipidated LC3 was not enhanced as much as chloroquine and nelfinavir treated Tsc2−/−MEFs,
indicating that mefloquine is not as potent as chloroquine at inhibiting autophagy in these cells. Given
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the weaker level of autophagy inhibition with mefloquine, we considered it unlikely that blockade of
autophagy was triggering the cell death response.
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Figure 4. Mefloquine and nelfinavir drug cytotoxicity is not associated with mTORC1 hyperactivity
and causes minimal autophagy inhibition. ( ) Tsc2 /−MEFs, NCI-H460, MCF7 and HCT116 cells
were p -t at d with 50 nM ra in (RAP) for 1 h, where indicat d, before b ing treated with
10 µM nelfinavi ) and 10 µM mefloquine (MQ) for 48 h. Cells were stained with DRAQ7 and
% cell death t r ined using flow cytometry. (B) Western blotting was carried out to determine
rp-S6 phosphorylation at Ser235/236 in the cells treated in (A) after 48 h of treatment. (C) Tsc2+/+ and
Tsc2−/− cells were treated with DMSO, 10 µM mefloquine (MQ), 20 µM chloroquine (CQ), 10 µM
mefloquine or 20 µM chloroquine combined with 10 µM nelfinavir for 3 h. Accumulation of lipidated
LC3-II were analyzed by Western blot. Total protein levels of β-actin were used as a loading control.
To explore alternative mechanisms that might cause cell death, the RNA sequencing data
was further analyzed to compare gene expression changes in the Tsc2+/+ and Tsc2−/− MEFs
(Figure 5A−C). Key genes involved in the regulation of metabolism and energy homeostasis were
markedly up-regulated in the Tsc2−/− MEFs during combined treatment with nelfinavir and
mefloquine. Of interest, PPARGC1α (typically referred to as PGC1α (peroxisome proliferator-activated
receptor gamma coactivator 1α)) was basally expressed at a higher level in Tsc2−/− MEFs when
compared to the Tsc2+/+ controls, which was further enhanced upon combined treatment with
nelfinavir and mefloquine. Transcriptionally regulated genes of PGC1α were also observed to be more
highly expressed in the Tsc2−/−MEFs when compared to wildtype. These included genes involved
in glucose and lipid metabolism, such as peroxisome proliferator-activated receptor delta (PPARδ) and
gamma (PPARγ) where there is more than a 2-fold increase in PPARδ gene expression in Tsc2−/−MEFs
compared to Tsc2+/+ MEFS and a nearly 17-fold difference in PPARγ expression. Expression of genes
involved in glycolysis were also upregulated, which is suggestive of metabolic stress. These genes
included pyruvate dehydrogenase kinase 1 (PDK1), pyruvate carboxylase (PCX), lactate dehydrogenase
B (LDHB) and glycerol-3-phosphate dehydrogenase 1 (GPD1). AMP-dependent protein kinase (AMPK)
is known to function upstream of PGC1α, and is involved in the gene-expression of PGC1α as well as
its activity [25]. AMPK-regulated genes involved in glucose metabolism/storage such as acetyl-CoA
carboxylase 2 (ACC2, encoded by the ACACB gene) and glycogen synthase 1 (GYS1) were expressed at
a much higher level in Tsc2−/−MEFs and were further increased upon drug treatment with nelfinavir
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and mefloquine. The overall increase of mRNA expression of key genes involved in energy metabolism
indicates that the Tsc2−/−MEFs are likely energy stressed.
To determine whether energy stress could be a possible mechanism of cell death, flow cytometry
with DRAQ7 labelling was carried out with samples treated for 48 h with either DMSO, or nelfinavir
and mefloquine combination in the presence or absence of methyl pyruvate (Figure 5D). Methyl
pyruvate can alleviate energy stress when supplemented to cells, as it is a direct substrate of the citric
acid cycle to produce energy by oxidative phosphorylation [26]. Methyl pyruvate partially rescued
nelfinavir and mefloquine induced cell death when supplemented to the Tsc2−/− MEFs (causing
a 40% rescue of cell death). We confirmed that methyl pyruvate partially restored energy homeostasis
within cells, as observed by a reduction in phosphorylated 5’-AMP-activated protein kinase (AMPK)
and acetyl-CoA carboxylase (ACC). Methyl pyruvate also reduced the protein levels of SESN2 at the
24 h time point (Figure 5E). To further assess the capacity of Tsc2−/− MEFs to effectively restore
energy stress, we examined phosphorylation levels of ACC after combined nelfinavir and mefloquine
treatment at 6 h and 24 h time points (Figure 5F). In the presence of methyl pyruvate, the Tsc2−/−
MEFs behaved similarly to the Tsc2+/+ MEFs after treatment with nelfinavir and mefloquine, where
ACC phosphorylation was increased at 6 h and was then restored to a level equivalent to untreated
cells at 24 h. In contrast, in the absence of methyl pyruvate the Tsc2−/−MEFs had a delayed induction
of ACC phosphorylation during nelfinavir and mefloquine treatment. For instance, phosphorylation of
ACC was only marginally enhanced at 6 h, but was then markedly elevated at 24 h. Expression of the
ER stress proteins, ATF4, CHOP and GADD34 were significantly reduced at 24 h, showing recovery of
ER stress. Collectively, our data shows that the Tsc2−/−MEF cells become energy stressed during the
longer time points of nelfinavir and mefloquine treatment while they recover from ER stress.
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Figure 5. Mefloquine and nelfinavir combined rug treatment induces cytotoxicity via energy stress in
Tsc2−/−MEFs. (A) The RNA sequencing data used for Figure 3C−E was assessed for gene-expression
of genes involved in energy homeostasis. A heatmap for a panel of energy stress-linked genes is shown.
Differences of mRNA expression between Tsc2+/+ and Tsc2−/−MEFs treated with mefloquine and
nelfinavir is shown as a volcano plot (B) and graphed (C). (D) Tsc2−/− cells were treated with DMSO,
10 µM mefloquine and 10 µM nelfinavir combination (MQ/NFV) or mefloquine/nelfinavir combination
with the addition of 8 mM methyl pyruvate (MQ/NFV/MP) for 48 h. Cells were then stained with
DRAQ7 and % cell death determined by flow cytometry. (E) Tsc2−/− were treated with either DMSO
or 10 µM mefloquine and 10 µM nelfinavir combination in the presence or absence of 8 mM methyl
pyruvate for 24 h and total and phosphorylated ACC and AMPK was determined by western blot.
(F) Tsc2+/+ and Tsc2−/− cells were treated with either DMSO or 10 µM mefloquine and 10 µM
nelfinavir combination in the presence or absence of 8 mM methyl pyruvate for 6 and 24 h, where
indicated. Total protein levels of ACC, CHOP GADD34 and ATF4 as well as phosphorylated ACC
were detected by Western blot.
3. Discussion
The central hypothesis of this study was to exploit the homeostatic vulnerabilities within
TSC2-deficient cells with mTORC1 hyperactivity. The volume of unfolded protein within the ER
is intensified by mTORC1 hyperactivity, caused by heightened levels of de novo protein translation
and reduced efficiency of autophagy to remove the unfolded protein. Consequently, cell lines lacking
TSC2 become more sensitive to drug treatments that induce ER stress. In this study, we employed
nelfinavir as the ER stress inducer, and mefloquine as a potential autophagy inhibitor. We revealed
that nelfinavir and mefloquine synergize to selectively kill TSC2-deficient cells. The concentrations of
both drugs used in this study are clinically viable. For instance, 10 µM falls within the concentration
range of mefl q ine found in patient s rum [27]. Regarding n lfinavir, the 10 µM concentration
used in this study is higher than the ma ufacturer recommended trough concentration (1−3 µM).
However, nelfinavir serum concentration has previously been reported in HIV patients at a similar
conc ntr tion, ranging from 4.96 µM [28] up to 18 µM [29]. In fact, it has been reported that nelfinavir
is well tol rated in canc r patients at dos s 2.5 times the FDA-approve dose for HIV management [30].
We observed that the combination of nelfinavir and mefloquine had a long-lasting effect on Tsc2−/−
tumor spheroids, when compared to single drug treatments. For instance, with mefloquine, despite
an increase in DRAQ7 staining, indicating a level of cell death, cell recovery and outgrowth from
the bulk tumor after drug withdrawal was apparent. However, no cells recovered when nelfinavir
was combined with mefloquine. As well as cells lacking Tsc2, the nelfinavir and mefloquine drug
combination was effective at killing sporadic cancer cell lines with aberrant signaling through the
TSC1/TSC2 signaling axis, with MCF7 cells being much more sensitive to the dual therapy when
compared to single drug treatments.
Through transcriptional profiling of nelfinavir and mefloquine treated cells, we observed an ER
stress signature at the early 6 h time-point of treatment, implying that ER stress might be involved in
the observed cytotoxic response. However, when we examined the longer time points of combined
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nelfinavir and mefloquine treatment, we observed recovery of the ER stress ATF4-CHOP signaling
pathway within the Tsc2−/−MEF cells. ER stress-mediated cell death occurs when the protein level of
CHOP remains persistently elevated over a long time course of drug treatment. Given the temporary
elevation of CHOP in the continued presence of drug in both the Tsc2+/+ and Tsc2−/−MEFs, our data
indicates a good level of ER stress recovery and excludes the possibility that CHOP triggers cell death.
Further analysis of the RNA sequencing data in the Tsc2−/− MEFs implied that energy
homeostasis pathways were elevated after co-treatment with nelfinavir and mefloquine. We rescued
a significant degree of cell death with methyl pyruvate, indicating that cytotoxicity by nelfinavir
and mefloquine was at least partially mediated through energy deficiency. Methyl pyruvate is
a methyl ester of pyruvic acid that restores cellular energy production downstream of glycolysis
by acting as a mitochondrial citric acid cycle substrate. While ER stress is unlikely the trigger of
cell death, recovery from ER stress might contribute to the depletion of energy through the de novo
protein synthesis of chaperone and heat shock proteins that are required for the unfolding and
refolding of protein aggregates in the ER, processes that heavily consume ATP. A recent study showed
that TSC2-knockdown leads to mitochondrial oxidative stress [31]. This degree of energy stress is
presumably why TSC2-deficent cells are vulnerable to conditions that induce energy starvation [32].
Mefloquine has shown promise as an anti-cancer drug in several cancer model settings. Liu et al.
showed that mefloquine (whether as a single agent or in combination with paclitaxel) induced
apoptosis in gastric cancer cell lines and gastric cancer xenograft mouse models [23]. PC3 cells,
a prostate cancer cell line, were also sensitive to mefloquine at 10 µM after 24 h of treatment [22].
However, no further toxicity was detected between 24 h to 72 h of mefloquine treatment, suggesting
that mefloquine may not be fully effective as a monotherapy. Mefloquine was shown to inhibit
autophagy, trigger ER stress and induced cell death in human breast cancer lines, and was more
cytotoxic when compared to chloroquine [33]. Our data is in line with these previous studies, except
we observed weaker inhibition of autophagy with mefloquine treatment. We further enhanced the
cytotoxic effectiveness of mefloquine with dual treatment with nelfinavir and determined that cell
death was caused by an imbalance in energy homeostasis. In the cancer setting, mefloquine is currently
in a phase I clinical factorial trial (NCT01430351) in combination with the DNA-damaging agent
temozolomide for glioblastoma multiforme. It should be noted that mefloquine has advantages over
chloroquine for the treatment of brain cancers, as mefloquine has better penetration through the blood
brain barrier. In summary, we show that mefloquine synergizes with nelfinavir to induce a high
degree of cell death through energy stress. There is clinical application for this drug combination
in the cancer setting, where we can exploit the lack of flexibility that cancer cells have in restoring
homeostatic balance.
4. Materials and Methods
4.1. Cell Culture and Drug Treatments
Tsc2-null ELT3-V3 and control ELT3-T3 cells re-expressing TSC2 were kindly provided by Cheryl
Walker (M.D. Anderson Cancer Centre, Houston, USA). Tsc2+/+ p53−/− and Tsc2−/− p53−/−
MEFs were kindly provided by David J. Kwiatkowski (Harvard University, Boston, MA, USA). Human
breast cancer (MCF7), human colorectal cancer (HCT116) and human lung carcinoma (NCI-H460) cell
lines were purchased from ATCC. All cell lines were routinely tested using the Venor GeM Classic PCR
kit from (CamBio) and were clear of mycoplasma. Cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM), while the MCF7 cell line was incubated in Roswell Park Memorial Institute (RPMI)
1640. Cell media was supplemented with 10% (v/v) Fetal Bovine Serum (FBS) and 100 U/mL Penicillin
and 100 µg/mL Streptomycin (Life Technologies Ltd., Paisley, UK). All cell lines were incubated at
37 ◦C, 5% (v/v) CO2 in a humidified incubator. Nelfinavir mesylate hydrate, chloroquine di-phosphate
salt, mefloquine hydrochloride, rapamycin, etoposide and thapsigargin were purchased from Sigma
Aldrich Ltd. (Gillingham, Dorset, UK). DMSO was used as a solvent to make stock solutions of
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etoposide (100 mM), mefloquine (50 mM), nelfinavir (30 mM), thapsigargin (10 mM) and rapamycin
(100 µM). Chloroquine was made fresh in culture medium at a 100 mM stock and further diluted
in culture medium to the required concentration before use. Drug(s) dissolved in DMSO or DMSO
vehicle control were added to cells in culture media so that they were diluted to a final concentration
that was below 0.8% (v/v) DMSO.
4.2. Flow Cytometry
Treated cells were collected and incubated with 3 µM DRAQ7 (Biostatus, Leicestershire, UK) at
room temperature for 10 min. Flow cytometry was performed using a FACS Calibur flow cytometer
(Becton Dickinson (Cowley, UK)) with excitation set at 488 nm and detection of fluorescence in log
mode at wavelengths greater than 695 nm. Cell Quest Pro software was used for signal acquisition.
A total of 10,000 events per sample were collected.
4.3. Western Blotting
S6K1, phospho-S6K1(Thr389), rpS6, phospho-rpS6(Ser235/236), IRE1α, CHOP, GADD34, ATF4,
TSC2, SESN2, AMPK, phospho-AMPK(Thr172), ACC, phospho-ACC (Ser79) and β-actin antibodies
were purchased from Cell Signaling Technology (Danvers, USA). LC3 antibodies were bought from
Novus Ltd. (Cambridge, UK). Cells were washed in ice-cold phosphate buffered saline (PBS) and
then lysed in cell lysis buffer (20 mM Tris (pH 7.5), 125 mM NaCl, 50 mM NaF, 5% (v/v) glycerol,
0.1% (v/v) Triton X-100, supplemented with 1 mM dithiothreitol (DTT), 1 µg/mL pepstatin, 20 µM
leupeptin, 1 mM benzamidine, 2 µM antipain, 0.1 mM PMSF, 1 mM sodium orthovanadate and 1 nM
okadaic acid prior to cell lysis). Cell lysates were sonicated using a diagenode bioruptor (Diagenode,
Seraing, Belgium) and centrifuged at 13,000 rpm for 8 min. Protein concentrations were determined
by a Bradford assay (Thermo Fisher Scientific, Paisley, UK). Samples were diluted in 4 × NuPAGE
loading sample buffer (Life Technologies) with 25 mM DTT and boiled at 70 ◦C for 10 min. Western
blot was performed as previously described [34].
4.4. mRNA Extraction and Reverse Transcription
Treated cells were washed in ice cold PBS then lysed using RNAprotect Cell Reagent (Qiagen, West
Sussex, UK). RNA concentrations were determined by measuring the absorbance at 260 nm and 280 nm
in a Nanodrop spectrophotometer. Total RNA from each sample (1 µg) was converted to copy DNA
(cDNA) using the Quantitect reverse transcription kit (Qiagen) following the manufacturer’s protocol.
4.5. XBP-1 Splicing
Protocol for XBP-1 splicing is as described in reference [19]. Xbp1 primers (forward: 5′-AAA
CAG AGT AGC AGC TCA GAC TGC-3′, reverse: 5′-TCC TTC TGG GTA GAC CTC TGG GA-3′, were
synthesized by MWG Operon-Eurofin (Ebersberg, Germany)). β-actin primers were purchased from
Qiagen (QT01136772). PCR was performed in an Applied Biosystems GeneAmp 9700 PCR system in
the following conditions: Initial denaturation step (94 ◦C, 3 min); 31 cycles of denaturation (94 ◦C, 45 s);
annealing step (60 ◦C, 30 s); extension step (72 ◦C, 1 min); final extension step (72 ◦C, 10 min). A 3%
(w/v) agarose (Appleton, Birmingham, UK) 1 × Tris-acetate-EDTA (4.84 g Tris-base (pH 8.0), 0.372 g
EDTA and 1.7 mL acetic acid in 1 L deionized water) was made with 0.005% (v/v) GelRed nucleic acid
stain (Biotium, Fremont, CA, USA). DNA samples were loaded with Orange G loading buffer (15 mL
30% (v/v) glycerol, 100 mg Orange G powder, deionized water, total volume 50 mL) and resolved on
the gel at 100 V. After 1 h, β-actin samples were analyzed. Samples were resolved for an additional 2 h
for XBP-1 splicing. PCR products of Xbp1 were 480 bp (unspliced) and 454 bp (spliced).
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4.6. Tumor Formation Assay
A 1.2% (w/v) agar solution in PBS (Difco Agar Noble (BD, Oxford, UK)) was diluted with DMEM
to a final concentration of 0.6% (w/v) then added to a 6 well plate and allowed to set. A total of
150,000 Tsc2−/− MEF cells were added to a 0.3% (w/v) agar-PBS:DMEM mixture and 3 mL was
layered on top and left to set. Plates were incubated overnight with 2 mL of DMEM. The following day,
the 2 mL of DMEM was replaced with DMEM containing either drugs or DMSO. Media and drugs
were refreshed every 48–72 h for 14 days. Images were taken using an EVOS XL Core camera (Life
Technologies). Tumor diameter was analyzed using Image J.
4.7. Tumor Outgrowth Assay
A total of 70 µl of 1.5% (w/v) agarose-PBS was added to each well of a 96 well plate and allowed to
set. A total of 1000 Tsc2−/−MEF cells in 140 µL complete DMEM were added to each well. Spheroids
were formed over 72 h. Following formation, spheroids were drug treated for 48 h. Cells were imaged
and then treated for 48 h. Treatment was refreshed and a final concentration of 3 µM DRAQ7 was
added to each well and incubated for an additional 48 h. Imaging and subsequent outgrowth was
performed as previously described [35].
4.8. RNA Sequencing
Total RNA quality and quantity was assessed using Agilent 2100 Bioanalyser and an RNA Nano
6000 kit (Agilent Technologies, Cheshire, UK). A total of 100–900 ng of total RNA with a RIN value >8
was used as the input and the sequencing libraries were prepared using the Illumina® TruSeq® RNA
sample preparation v2. (Illumina Inc., Cambridge, UK). The steps included two rounds of purification
of the polyA containing mRNA molecules using oligo-dT attached magnetic beads followed by RNA
fragmentation, 1st strand cDNA synthesis, 2nd strand cDNA synthesis, adenylation of 3’-ends, adapter
ligation, PCR amplification (15 cycles) and validation. The manufacturer’s instructions were followed.
The libraries were validated using the Agilent 2100 Bioanalyser and a high-sensitivity kit (Agilent
Technologies) to ascertain the insert size, and the Qubit® (Life Technologies) was used to perform the
fluorometric quantitation. Following validation, the libraries were normalized to 4 nM and pooled
together. The pool was then sequenced using a 75 base paired-end (2 × 75 bp PE) dual index read
format on the Illumina® HiSeq2500 in rapid mode according to the manufacturer’s instructions.
The pool was then sequenced using a 75 base paired-end (2 × 75 bp PE) dual index read format on
the Illumina® HiSeq2500 in high-output mode according to the manufacturer’s instructions. Quality
control checks of the resultant reads were performed using FastQC before mapping to the UCSC
mouse mm10 reference genome using Tophat and Bowtie. Differentially expressed transcripts were
identified using a DeSeq2 analysis [36] on normalized count data with the design formula setup to
analyze all pairwise comparisons in the dataset using contrasts. The resultant p-values were corrected
for multiple testing and false discovery issues using the FDR method. Genes involved in cell survival
were selected based on GO: 0008219 (cell death) from the complete list on AmiGo 2.
4.9. Statistical Analysis
All experiments were carried out with a minimum of three biological repeats. Where applicable,
results are written as mean with a +/− St-Dev. Either a two-way ANOVA (with Bonferroni’s multiple
comparison post-hoc test) or one-way ANOVA (with Tukey’s multiple comparison post-hoc test) was
used to determine statistical significance. Significance was reported as a p value: * p < 0.05, ** p < 0.01,
*** p < 0.001.
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5. Conclusions
In conclusion, mefloquine synergizes with nelfinavir to induce a high degree of cell death through
energy stress. There is potential to use mefloquine with nelfinavir in the cancer setting, to treat cancer
cells that have a lack of flexibility in restoring homeostatic balance.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/10/10/375/
s1, Table S1: RNAseq raw data of mefloquine and nelfinavir treatment of Tsc2 MEFs, Table S2: RNAseq of Tsc2−/−
compared to Tsc2+/+ after mefloquine and nelfinavir treatment.
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